Efficient gene transfer and durable transgene expression in grafted rabbit veins

Human Gene Therapy

Volumn 26, Issue 1, 2015, Pages 47-58

  Du, Liang ^a   Zhang, Jingwan ^a   Clowes, Alexander W ^b   Dichek, David A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN A1; DNA; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CONTROLLED STUDY; GENE EXPRESSION ASSAY; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GRAFT PATENCY; IMMUNOHISTOLOGY; JUGULAR VEIN; MALE; NEOINTIMA; NONHUMAN; RABBIT MODEL; TRANSGENE; TUNICA MEDIA; VASCULAR REMODELING; VEIN DIAMETER; VEIN GRAFT; VIRAL GENE DELIVERY SYSTEM; ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; ANIMAL; GENE EXPRESSION; GENE VECTOR; GENETICS; METABOLISM; RABBIT; REPORTER GENE; TIME FACTOR; VEIN;

ORYCTOLAGUS CUNICULUS;

ADENOVIRIDAE; ANIMALS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; MALE; RABBITS; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES; VEINS;

EID: 84921479985     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.084     Document Type: Article

References (62)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
2. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009;373:1190-1197.
3. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-972.
4. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629-638.
5. Harskamp RE, Lopes RD, Baisden CE, et al. Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. Ann Surg 2013;257:824-833.
6. Tatoulis J, Buxton BF, and Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. Ann Thorac Surg 2004;77:93-101.
7. Mehta RH, Ferguson TB, Lopes RD, et al. Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. Circulation 2011;124:280-288.
8. Sabik JF, III. Understanding saphenous vein graft patency. Circulation 2011;124:273-275.
9. Goldman S, Copeland J, Moritz T, et al. Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: results of a VA Cooperative study. Circulation 1994;89:1138-1143.
10. Post Coronary Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
11. Southerland KW, Frazier SB, Bowles DE, et al. Gene therapy for the prevention of vein graft disease. Transl Res 2013;161:321-338.
12. Lopes RD, Mehta RH, Hafley GE, et al. Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. Circulation 2012;125: 749-756.
13. Lee MS, Park SJ, Kandzari DE, et al. Saphenous vein graft intervention. JACC Cardiovasc Interv 2011;4:831-843.
14. Harskamp RE, Beijk MA, Damman P, et al. Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure. J Cardiovasc Med (Hagerstown) 2013;14:438-445.
15. Bradshaw AC, and Baker AH. Gene therapy for cardiovascular disease: perspectives and potential. Vascul Pharmacol 2013;58:174-181.
16. Motwani JG, and Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998;97:916-931.
17. Conti VR, and Hunter GC. Gene therapy and vein graft patency in coronary artery bypass graft surgery. JAMA 2005;294:2495-2497.
18. Flynn R, Qian K, Tang C, et al. Expression of apolipoprotein A-I in rabbit carotid endothelium protects against atherosclerosis. Mol Ther 2011;19:1833-1841.
19. Vassalli G, Agah R, Qiao R, et al. A mouse model of arterial gene transfer: antigen-specific immunity is a minor determinant of the early loss of adenovirus-mediated transgene expression. Circ Res 1999;85:e25-e32.
20. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cremediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996;93:13565-13570.
21. Flynn R, Buckler JM, Tang C, et al. Helper-dependent adenoviral vectors are superior in vitro to first-generation vectors for endothelial cell-targeted gene therapy. Mol Ther 2010;18:2121-2129.
22. Chen L, Anton M, and Graham FL. Production and characterization of human 293 cell lines expressing the sitespecific recombinase Cre. Somat Cell Mol Genet 1996; 22:477-488.
23. Dronadula N, Du L, Flynn R, et al. Construction of a novel expression cassette for increasing transgene expression in vivo in endothelial cells of large blood vessels. Gene Ther 2011;18:501-508.
24. Mittereder N, March KL, and Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996;70:7498-7509.
25. Du L, Dronadula N, Tanaka S, et al. Helper-dependent adenoviral vector achieves prolonged, stable expression of interleukin-10 in rabbit carotid arteries but does not limit early atherogenesis. Hum Gene Ther 2011;22:959-968.
26. Jiang Z, Wu L, Miller BL, et al. A novel vein graft model: adaptation to differential flow environments. Am J Physiol Heart Circ Physiol 2004;286:H240-H245.
27. Zwolak RM, Kirkman TR, and Clowes AW. Atherosclerosis in rabbit vein grafts. Arteriosclerosis 1989;9:374-379.
28. Schneider DB, Vassalli G, Wen S, et al. Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 2000;20:298-308.
29. Zwolak RM, Adams MC, and Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg 1987;5:126-136.
30. Robertson KE, McDonald RA, Oldroyd KG, et al. Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role? Pharmacol Ther 2012;136:23-34.
31. Channon KM, Fulton GJ, Gray JL, et al. Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovasc Res 1997;35:505-513.
32. Lemarchand P, Jones M, Yamada I, et al. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993;72:1132-1138.
33. Channon KM, Qian H, Youngblood SA, et al. Acute hostmediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function. Circ Res 1998;82:1253-1262.
34. Wan S, George SJ, Nicklin SA, et al. Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther 2004;9:689-698.
35. Davies MG, Huynh TT, Fulton GJ, et al. G protein signaling and vein graft intimal hyperplasia: reduction of intimal hyperplasia in vein grafts by a Gβγ inhibitor suggests a major role of G protein signaling in lesion development. Arterioscler Thromb Vasc Biol 1998;18:1275-1280.
36. Kibbe MR, Tzeng E, Gleixner SL, et al. Adenovirusmediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 2001;34:156-165.
37. West NE, Qian H, Guzik TJ, et al. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 2001;104: 1526-1532.
38. Nwasokwa ON. Coronary artery bypass graft disease. Ann Intern Med 1995;123:528-545.
39. Sarjeant JM, and Rabinovitch M. Understanding and treating vein graft atherosclerosis. Cardiovasc Pathol 2002;11: 263-271.
40. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005;294:2446-2454.
41. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006;43:742-751; discussion 751.
42. Kilian EG, Eifert S, Beiras-Fernandez A, et al. Adenoassociated virus-mediated gene transfer in a rabbit vein graft model. Circ J 2008;72:1700-1704.
43. Eefting D, Bot I, De Vries MR, et al. Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. J Vasc Surg 2009;50:152-160.
44. Wen S, Graf S, Massey PG, et al. Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 2004;110:1484-1491.
45. Jiang B, Qian K, Du L, et al. Helper-dependent adenovirus is superior to first-generation adenovirus for expressing transgenes in atherosclerosis-prone arteries. Arterioscler Thromb Vasc Biol 2011;31:1317-1325.
46. Schulick AH, Vassalli G, Dunn PF, et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries: potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 1997;99:209-219.
47. Flugelman MY, Jaklitsch MT, Newman KD, et al. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation 1992;85:1110-1117.
48. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-158.
49. Conte MS. Molecular engineering of vein bypass grafts. J Vasc Surg 2007;45(Suppl. A):A74-A81.
50. Mann MJ, Gibbons GH, Kernoff RS, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A 1995;92:4502-4506.
51. Schwartz SM, Deblois D, and O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res 1995;77: 445-465.
52. Newby AC, and Baker AH. Targets for gene therapy of vein grafts. Curr Opin Cardiol 1999;14:489-494.
53. Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50(Suppl.): S189-S194.
54. Chen S-J, Wilson JM, and Muller DWM. Adenovirusmediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 1994; 89:1922-1928.
55. Turunen P, Puhakka HL, Heikura T, et al. Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: combination gene therapy in the treatment of vein graft stenosis in rabbits. Hum Gene Ther 2006;17:405-414.
56. Newman KD, Dunn PF, Owens JW, et al. Adenovirusmediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995;96:2955-2965.
57. Lafont A, Loirand G, Pacaud P, et al. Vasomotor dysfunction early after exposure of normal rabbit arteries to an adenoviral vector. Hum Gene Ther 1997;8:1033-1040.
58. Lonn U, Peterzen B, Granfeldt H, et al. Coronary artery operation supported by the Hemopump: an experimental study on pig. Ann Thorac Surg 1994;58:516-518.
59. Armstrong ML, and Heistad DD. Animal models of atherosclerosis. Atherosclerosis 1990;85:15-23.
60. Angelini GD, Izzat MB, Bryan AJ, et al. External stenting reduces early medial and neointimal thickening in a pig model of arteriovenous bypass grafting. J Thorac Cardiovasc Surg 1996;112:79-84.
61. Schachner T, Laufer G, and Bonatti J. In vivo (animal) models of vein graft disease. Eur J Cardiothorac Surg 2006; 30:451-463.
62. Cremers B, Milewski K, Clever YP, et al. Long-term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis. Catheter Cardiovasc Interv 2012;80:603-610.